Navigation Links
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:5/12/2008

rding the company's future plans, objectives, performance, growth or the company's underlying assumptions. The words "may", "would", "will", "expect," "intend", "plan", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only expectations, and that the company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: that HspE7 is more active with an elevated does of adjuvant; that administration of HspE7 induces T-cell responses that are therapeutic; that administration of HspE7 results in an E7-specific T-cell immune response; that such an immune response may be associated with objective clinical responses in patients with CIN; that HspE7 may successfully induce a targeted immune response to effectively treat CIN; the potential of HspE7 to treat HPV-16 induced CIN; and initiation of our Phase 2 clinical study in patients with CIN 2/3 in mid-2008.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that immunology responses may not be a predictor of clinical benefit; that immunological findings in our first three cohorts may not be consistent with findings from our fourth cohort and future clinical studies; that safety and tolerability findings in all four cohorts may not be consistent with findings from future clinical studies; that results from future clinical trials will not be consistent with our expectations; that we will not be able to recruit patients
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015  Accuray Incorporated (Nasdaq: ARAY ... agreement with MIM Software Inc. to further develop ... and CyberKnife ® product portfolios. The new software ... This is Accuray,s second collaboration with MIM; the ... first iPad-based treatment plan review capability, PlanTouch™. ...
(Date:4/30/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world leader ... restore failing hearts, said today it will participate in ... on Thursday, May 14. D. Keith ... an update on the company, beginning at 10:40 a.m., ... The presentation will be available through the conference ...
(Date:4/30/2015)... Corporation (Nasdaq: DRRX ) announced today financial results ... $4.8 million and net loss was $4.9 million for ... to total revenues of $6.3 million and net loss ... 31, 2014.At March 31, 2015, we had cash and ... of $34.9 million at December 31, 2014.  Subsequent to ...
Breaking Medicine Technology:Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
... THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 ... Inc. (NYSE: PFE ) today announced new ... body of evidence supporting the efficacy and safety profile ... the United States (U.S.). Eighteen abstracts across four indications, ...
... May 25, 2011 Boston Scientific Corporation (NYSE: ... U.S. Food and Drug Administration (FDA) to market its 2.25 ... in vessels as small as 2.25 mm in diameter.  The ... The PROMUS Stent features a thin-strut, open-cell design ...
Cached Medicine Technology:Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 2Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 3Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 4Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 5Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 6Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 7Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 8Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 9Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 10Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 11Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 12Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions 13Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System 4
(Date:5/1/2015)... 02, 2015 IDLife LLC, a health ... to announce the addition of its newest partner and ... life long athlete, growing up in gymnastics and competitive ... by becoming a personal trainer and helping others achieve ... of several TV shows highlighting her stunning physique and ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood ... their reclaimed wood products at the 27th annual International ... in NYC this May. Their newest offerings, Vat 35, ... texture and color to North America's platform for global ... and color in the design world and we're excited ...
(Date:5/1/2015)... Royal River Natural Foods, a locally-owned independent natural ... study that found two natural nutrients, glucosamine and chondroitin, ... as well as standard drug treatment after six months ... The report is part of the May 2015 issue ... Royal River Natural Foods publishes for free each month ...
(Date:5/1/2015)... 2015 TROY Healthcare Solutions is proud ... User Group (RUG) Conference in Atlanta, GA from May ... Group Conference provides a forum for client-to-client presentations, continuing ... aspects of electronic medical record operations, as well as ... , In addition to sponsoring the event, TROY Healthcare ...
(Date:5/1/2015)... May 01, 2015 Hope For The ... of Hope For The Warriors® and military families. All ... support Hope For The Warriors®, a national nonprofit dedicated ... unit, and restoring hope for our service members and ... All American Ford collected and matched small autograph fee ...
Breaking Medicine News(10 mins):Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2
... geographical areas in Southeast England according to a new study ... Health . The study shows that the occurrence of cervical ... Currin and her colleagues at the Thames Cancer Registry of ... cancer diagnosed between 2001 and 2005 in London, Kent, Surrey ...
... and programming in Canadian long-term care facilities fall short ... , Led by professor of Community Health and Epidemiology ... is the first comprehensive examination of these resources and ... that vulnerable long-term care residents be protected from largely ...
... 19 Esphera3 International (E3I) is a broad ... of "Patient Focused Care." Currently engaged in multiple ... of a partnered care health approach including operational ... financial operations of healthcare.E3I and its channel partners ...
... SHELBY TOWNSHIP, Mich., Feb. 19 Dr. Brett Kotlus ... Allure Medical Blog to share information,about new ... their practice. "I find that patients at our ... to sort through the tremendous,amount of information available on ...
... save lives and reduce disability, but less than 3% of ... (HealthDay News) -- A powerful clot-busting drug approved by the ... in 1996 is still rarely used in Medicare patients, new ... 495,000 admissions for stroke at the 4,750 hospitals evaluated were ...
... Insulet Corporation, (Nasdaq: PODD ), the leader ... Management System, announced plans to release its financial results ... Thursday, March 5, 2009 after the close of the ... 5:00 p.m. Eastern Time on Thursday, March 5, 2009 ...
Cached Medicine News:Health News:Infection prevention falls short in Canadian long-term care facilities 2Health News:Esphera3 International Founded on 'Patient Focused Care' 2Health News:Your Doctor Has a Blog 2Health News:Your Doctor Has a Blog 3Health News:Few Stroke Patients Get Clot-Busting Drug 2Health News:Few Stroke Patients Get Clot-Busting Drug 3
... extends that easy, breezy, beautiful image to ... an array of stylish colors, trendy shapes, ... is designed to target the broad demographics ... affordability,and high-quality, fashionable frames. The Cover Girl ...
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... Brook Brothers and Luxottica Group dates ... materials and a slender line, the ... features of the style of this ... style and affordable to everyone that ...
... Ray-Ban brand debuted in 1937 with the ... was added to Luxottica Group's brand portfolio ... show business celebrities since day one, Ray-Bans ... far the best-selling sunglasses in the world. ...
Medicine Products: